GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)
Panadol is approved by the TGA for the effective relief of backache. The results of the PACE study are not expected to lead to changes in the current recommendations that paracetamol should remain a first line analgesic in low back pain.
GSK advocates continual research into the effective use of paracetamol and will review any new studies within the broader context of existing research.
The PACE study was designed to look at the benefits of paracetamol on recovery from acute low back pain. Paracetamol was well tolerated in this study. The study adds to our understanding of how best to manage acute low back pain, highlighting the importance of advice and reassurance to patients suffering from low back pain in improving time to recovery.
For further information contact:
| Joanne Clark |
| Tel: +61 2 9684 0741 |
| Mobile: +61 407 829 209 |
| Email: joanne.v.clark@gsk.com |
Follow us on Twitter - @GSK_AU
